Mallinckrodt acquired Cadence Pharmaceuticals for $14.00 per share in cash, totaling approximately $1.4B. The deal added IV acetaminophen Ofirmev—on formulary at 2,350+ U.S. hospitals—to Mallinckrodt's specialty hospital portfolio. Tender offer expired March 18 and the deal closed March 19, 2014.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedFeb 26, 2014
ClosedMar 19, 2014
Deal value$1.4B
Deal typeAcquisition/Merger
Therapeutic areaAcute pain in hospital setting
IndicationsAcute pain in hospital setting
Key assetsOfirmev (IV acetaminophen)
MechanismCyclooxygenase inhibitor / central analgesic (IV acetaminophen)